|
LIN52 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.71209999511035E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.12999999976904E-07 |
| Normal-vs-Stage2 |
2.973300E-04 |
| Normal-vs-Stage3 |
1.37989999982047E-07 |
| Normal-vs-Stage4 |
1.96880000002952E-06 |
| Stage1-vs-Stage2 |
9.489000E-01 |
| Stage1-vs-Stage3 |
2.764800E-01 |
| Stage1-vs-Stage4 |
1.895800E-01 |
| Stage2-vs-Stage3 |
5.029000E-01 |
| Stage2-vs-Stage4 |
3.496200E-01 |
| Stage3-vs-Stage4 |
6.444800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.99960001282074E-09 |
| Normal-vs-AfricanAmerican |
1.030420E-01 |
| Normal-vs-Asian |
9.162500E-03 |
| Caucasian-vs-AfricanAmerican |
2.486000E-02 |
| Caucasian-vs-Asian |
4.380500E-02 |
| AfricanAmerican-vs-Asian |
5.691400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.28800001167428E-09 |
| Normal-vs-Female |
3.93400000020527E-07 |
| Male-vs-Female |
4.111600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.4835999999917E-05 |
| Normal-vs-Age(41-60Yrs) |
7.50419999473451E-08 |
| Normal-vs-Age(61-80Yrs) |
1.1701000002251E-07 |
| Normal-vs-Age(81-100Yrs) |
5.198900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.397800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.430830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.663600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.052200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.635600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.910600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.863000E-01 |
| Classical-VS-Follicular |
8.456300E-02 |
| Classical-VS-Other |
1.289170E-01 |
| Classical-VS-Normal |
9.93260000026197E-07 |
| Tall-VS-Follicular |
9.317400E-01 |
| Tall-VS-Other |
2.797800E-01 |
| Tall-VS-Normal |
6.1997999999952E-05 |
| Follicular-VS-Other |
4.066800E-01 |
| Follicular-VS-Normal |
9.3358999997406E-07 |
| Other-VS-Normal |
2.181600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.10380000379374E-08 |
| Normal-vs-N1 |
1.96050000000891E-06 |
| N0-vs-N1 |
2.304600E-01 |
|
|
